UK NHS trial shows promise of a single-dose psilocybin with therapy for hard-to-treat depression
A UK National Health Service–based phase 2 feasibility randomized trial tested a single 25‑mg dose of psilocybin with psychological support versus placebo in 60 adults with treatment‑resistant major depressive disorder. At three and six weeks, the psilocybin group showed large, clinically meaningful reductions on the MADRS compared with placebo (about a 10–13 point advantage) and higher response/remission rates, with improvements in anxiety and well‑being. Adverse events were mostly mild and not clearly linked to the drug, and blinding was imperfect, suggesting expectancy effects contributed to the outcome. Feasibility metrics (recruitment, retention, data completeness) were favorable, supporting larger efficacy trials and consideration of cost‑effectiveness in public healthcare. Overall, the study demonstrates the practicality of delivering psilocybin‑assisted therapy in NHS settings, while recognizing limitations that future trials should address.
